CN115605226A - 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体 - Google Patents

具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体 Download PDF

Info

Publication number
CN115605226A
CN115605226A CN202180038086.5A CN202180038086A CN115605226A CN 115605226 A CN115605226 A CN 115605226A CN 202180038086 A CN202180038086 A CN 202180038086A CN 115605226 A CN115605226 A CN 115605226A
Authority
CN
China
Prior art keywords
animal
oligopeptide
substituted
composition
feed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038086.5A
Other languages
English (en)
Chinese (zh)
Inventor
H·D·小纳勒
B·卡尔滕伯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrivert Inc
Original Assignee
Nutrivert Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrivert Inc filed Critical Nutrivert Inc
Publication of CN115605226A publication Critical patent/CN115605226A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180038086.5A 2020-03-26 2021-03-25 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体 Pending CN115605226A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000364P 2020-03-26 2020-03-26
US63/000364 2020-03-26
PCT/US2021/024142 WO2021195372A1 (en) 2020-03-26 2021-03-25 Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Publications (1)

Publication Number Publication Date
CN115605226A true CN115605226A (zh) 2023-01-13

Family

ID=77892334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038086.5A Pending CN115605226A (zh) 2020-03-26 2021-03-25 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体

Country Status (13)

Country Link
US (1) US12492222B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126040B1 (cg-RX-API-DMAC7.html)
JP (1) JP7667177B2 (cg-RX-API-DMAC7.html)
KR (1) KR102897673B1 (cg-RX-API-DMAC7.html)
CN (1) CN115605226A (cg-RX-API-DMAC7.html)
AU (1) AU2021241625B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019202A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172936A1 (cg-RX-API-DMAC7.html)
ES (1) ES3014076T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022011751A (cg-RX-API-DMAC7.html)
PL (1) PL4126040T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021195372A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210586B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
EP3946369A4 (en) 2019-03-26 2023-10-18 University Of Massachusetts MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
AU2021244600A1 (en) 2020-03-26 2022-11-03 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
CN115605226A (zh) 2020-03-26 2023-01-13 纽特莱特公司(Us) 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
WO2024102639A1 (en) * 2022-11-08 2024-05-16 The Scripps Research Institute N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693998A (en) * 1978-06-05 1987-09-15 Agence Nationale De Valorisation De La Rechersche Novel compounds of the muramyl peptide
CN1162920A (zh) * 1994-09-21 1997-10-22 英国佩普技术有限公司 胞壁酰肽化合物的应用
WO1998009989A1 (en) * 1996-09-06 1998-03-12 Peptech (Uk) Limited The use of muramylpeptides in the treatment of myelosuppressed or otherwise immunocompromised states

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9011830B (sl) 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
JPH0655107B2 (ja) 1991-03-13 1994-07-27 全国農業協同組合連合会 家畜,家禽,および魚介類用の抗仮性狂犬病ならびに抗病性飼料および飼料用添加物
WO1993013791A1 (en) 1992-01-20 1993-07-22 Peptech (Uk) Limited Use of muramyl peptides for enhancing animal production
MX9301789A (es) 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
RU2375047C2 (ru) 2004-03-26 2009-12-10 Лек Фармасьютиклз Д.Д. Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
CA2666814A1 (en) 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
KR20100059863A (ko) 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 티모신 베타 4 단독 또는 세크로핀 a와의 배합물의 용도
CN101918001B (zh) 2007-12-06 2016-11-16 英特威国际有限公司 使用醋酸美仑孕酮和齐帕特罗或其盐的联合治疗
CN101756026A (zh) 2008-12-11 2010-06-30 天津瑞贝特科技发展有限公司 增强虾、蟹硬壳速度的营养组合物及其制备方法、应用
DE102009002044A1 (de) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptide als Futtermitteladditive
BR112013027845A2 (pt) 2011-05-18 2017-01-03 Ajinomoto Kk Imunoestimulante, ração, método para produzir um imunoestimulante, e, método para imunoestimulação
CN102578414B (zh) 2012-02-23 2014-01-01 青岛绿曼生物工程有限公司 促进猪生长育肥、提高免疫力的复方蜂胶饲料添加剂及其制备方法
WO2013172517A1 (ko) 2012-05-16 2013-11-21 서울대학교산학협력단 뮤라밀-다이펩타이드를 포함하는 골소실 예방, 골재생 또는 골형성 촉진용 약학 조성물
EP2975046A1 (en) * 2014-07-16 2016-01-20 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Novel compounds
WO2017068149A1 (en) 2015-10-21 2017-04-27 Cysal Gmbh Aspartyl-dipeptides for aquaculture
EP3387005B1 (en) * 2015-12-10 2022-08-24 Bharat Biotech International Limited Novel muramyl peptide derivative compound, synthesis and uses thereof
CN109562158A (zh) 2016-06-23 2019-04-02 纽特莱特公司 在动物中促进生长和提高饲料转化率的方法
TWI634902B (zh) * 2017-10-28 2018-09-11 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 Use of glucosamine peptide compounds for the treatment of abnormal liver metabolism
WO2020019128A1 (zh) 2018-07-23 2020-01-30 深圳市健元医药科技有限公司 丙氨酸—赖氨酸—谷氨酸三肽衍生物及其应用
CN115605226A (zh) 2020-03-26 2023-01-13 纽特莱特公司(Us) 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693998A (en) * 1978-06-05 1987-09-15 Agence Nationale De Valorisation De La Rechersche Novel compounds of the muramyl peptide
CN1162920A (zh) * 1994-09-21 1997-10-22 英国佩普技术有限公司 胞壁酰肽化合物的应用
WO1998009989A1 (en) * 1996-09-06 1998-03-12 Peptech (Uk) Limited The use of muramylpeptides in the treatment of myelosuppressed or otherwise immunocompromised states

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBCHEM CID 118658462: "(2R)-2-amino-3-[(2S)-2-[(2R)-5-amino-2-[[(2S)-2-[[(2R)-2-hydroxypropanoyl]amino]propanoyl]amino]-5-oxopentanoyl]oxy-3-(carboxymethylamino)-3-oxopropyl]sulfanylpropanoic acid", pages 1, Retrieved from the Internet <URL:https://pubchem.ncbi.nlm.nih.gov/compound/118658462> *

Also Published As

Publication number Publication date
NZ792610A (en) 2025-07-25
KR102897673B1 (ko) 2025-12-09
ZA202210586B (en) 2023-05-31
JP7667177B2 (ja) 2025-04-22
AU2021241625B2 (en) 2025-04-24
AU2021241625A1 (en) 2022-11-10
JP2023518973A (ja) 2023-05-09
EP4126040A4 (en) 2024-04-24
EP4126040A1 (en) 2023-02-08
US20230174577A1 (en) 2023-06-08
WO2021195372A1 (en) 2021-09-30
EP4126040C0 (en) 2025-02-19
ES3014076T3 (en) 2025-04-16
BR112022019202A2 (pt) 2022-11-08
PL4126040T3 (pl) 2025-04-28
KR20220158773A (ko) 2022-12-01
CA3172936A1 (en) 2021-09-30
EP4126040B1 (en) 2025-02-19
US12492222B2 (en) 2025-12-09
MX2022011751A (es) 2022-12-02

Similar Documents

Publication Publication Date Title
KR102897673B1 (ko) 항염증 및 성장 촉진 활성을 갖는 데스아세틸글루코사민 무라밀 디펩티드의 친지성 거울상이성질체
JP4151765B2 (ja) 免疫調節活性を有する新規な置換プリニル誘導体
JP7604666B2 (ja) 代謝及び肝臓障害の処置のための組成物及び方法
JP7642830B2 (ja) 代謝及び肝臓障害の処置のための組成物及び方法
Kaur et al. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects
US10626139B2 (en) Cationic steroidal antimicrobial compounds
TWI759301B (zh) 聚乙二醇化卡非佐米化合物
JP2013040209A (ja) Tlrアゴニスト
CN114340643A (zh) 用于car-t细胞治疗的脂质-荧光素缀合物的设计和有效合成
KR20130042501A (ko) 이중기능 복합체의 화학합성 및 항 종양과 항 종양 전이 작용
KR20230048358A (ko) 질환 및 장애를 치료하기 위한 조성물 및 방법
CN119948050A (zh) 用于治疗代谢和肝脏病症的组合物和方法
FR2630649A1 (fr) Sels d&#39;addition d&#39;acides de derives n-acyles de la taurine ou de la glycine, leur preparation et leur utilisation
EP3474894A1 (en) Methods to promote growth and improve feed conversion in animals
US20230065479A1 (en) Liver-targeting compound having thyroid hormone receptor agonist characteristics and pharmaceutical composition thereof
US20130345117A1 (en) Peptide-phospholipid conjugates
WO2025006896A1 (en) Low dose muramyl dipeptide analogue-containing compositions and methods of using same for immunoprotection
CN112592379A (zh) 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
US20230181728A1 (en) Adjuvanted conjugate opioid vaccine
EP3838347A1 (en) Evernimicin for treating diseases like necrotic enteritis
JP2025520449A (ja) X-ald治療のための甲状腺ベータ作動薬投与計画
HK40072710A (en) Design and efficient synthesis of lipid-fluorescein conjugates for car-t cell therapy
HK1262091A1 (en) Pegylated carfilzomib compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Georgia, USA

Applicant after: Newlight Ltd.

Address before: Georgia, USA

Applicant before: Nutrivert LLC

Country or region before: U.S.A.